Gabapentinoids in Chronic Kidney Disease: A Closer Look at Respiratory Risk.

Area of Science:

• Pharmacology
• Nephrology
• Critical Care Medicine

Background:

• The FDA issued a warning in 2019 about respiratory depression risks associated with gabapentin, particularly when combined with CNS depressants.
• Limited data exist on respiratory risks of gabapentinoids in hospitalized patients with renal dysfunction.

Purpose of the Study:

• To evaluate the association between gabapentinoid use and respiratory depression in hospitalized patients diagnosed with chronic kidney disease (CKD).

Main Methods:

• A retrospective cohort study of adult inpatients with CKD stages III, V receiving multimodal pain management.
• Exclusion criteria included epilepsy, anxiety disorders, restless leg syndrome, acute respiratory or hepatic conditions, and ICU admission.
• The primary outcome was a composite measure of respiratory depression, including interventions like high-flow nasal cannula, BiPAP, mechanical ventilation, and naloxone administration.

Main Results:

• Gabapentinoid use was associated with a significantly higher risk of respiratory depression (OR: 1.71; 95% CI: 1.02-2.89) after adjusting for confounders.
• A dose-dependent relationship was observed for both gabapentin and pregabalin, with higher doses correlating with increased respiratory depression.
• No significant differences were found in secondary outcomes such as altered mental status or falls between the groups.

Conclusions:

• Gabapentinoid administration in hospitalized patients with CKD is linked to an increased incidence of respiratory depression.
• Findings underscore the necessity for cautious prescribing, dose adjustment, and vigilant monitoring of gabapentinoids in CKD patients.